XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Total
Balance at beginning of period at Dec. 31, 2022 $ 1 $ 880,832 $ (897) $ (682,315) $ 197,621
Balance at beginning of period (in shares) at Dec. 31, 2022 66,688,647        
Increase (Decrease) in Stockholders' Equity          
Issuance of common stock in connection with vesting of restricted stock units (in shares) 517,378        
Unrealized gain (loss) on marketable securities     543   543
Stock-based compensation expense   6,806     6,806
Net loss       (28,160) (28,160)
Balance at end of period at Mar. 31, 2023 $ 1 887,638 (354) (710,475) 176,810
Balance at end of period (in shares) at Mar. 31, 2023 67,206,025        
Balance at beginning of period at Dec. 31, 2023 $ 1 928,080 (106) (770,796) $ 157,179
Balance at beginning of period (in shares) at Dec. 31, 2023 70,894,889       70,894,889
Increase (Decrease) in Stockholders' Equity          
Issuance of common stock in connection with vesting of restricted stock units   (55)     $ (55)
Issuance of common stock in connection with vesting of restricted stock units (in shares) 353,128        
Unrealized gain (loss) on marketable securities     (258)   (258)
Stock-based compensation expense   2,089     2,089
Net loss       (16,941) (16,941)
Balance at end of period at Mar. 31, 2024 $ 1 $ 930,114 $ (364) $ (787,737) $ 142,014
Balance at end of period (in shares) at Mar. 31, 2024 71,248,017       71,248,017